NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

CEO John Houston emphasized that Arvinas is nearing key milestones, including the first Phase 3 topline data for vepdegestrant (vepdeg) from the VERITAC-2 trial expected in Q1 2025. He noted that this ...

The Nasdaq is one of the top three most-followed stock market indices in the United States, comprising over 2,500 stocks.

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial isanticipated in 1Q25 –– Presented Phase 1b data from the TACTIVE-U ...